Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes

Abstract

Background. Human immunodeficiency virus (HIV)-1 drug resistance mutations (DRMs) often accompany treatment failure. Although subtype differences are widely studied, DRM comparisons between subtypes either focus on specific geographic regions or include populations with heterogeneous treatments.Methods. We characterized DRM patterns following first-line failure and their impact on future treatment in a global, multi-subtype reverse-transcriptase sequence dataset. We developed a hierarchical modeling approach to address the high-dimensional challenge of modeling and comparing frequencies of multiple DRMs in varying first-line regimens, durations, and subtypes. Drug resistance mutation co-occurrence was characterized using a novel application of a statistical network model.Results. In 1425 sequences, 202 subtype B, 696 C, 44 G, 351 circulating recombinant forms (CRF)01_AE, 58 CRF02_AG, and 74 from other subtypes mutation frequencies were higher in subtypes C and CRF01_AE compared with B overall. Mutation frequency increased by 9%–20% at reverse transcriptase positions 41, 67, 70, 184, 215, and 219 in subtype C and CRF01_AE vs B. Subtype C and CRF01_AE exhibited higher predicted cross-resistance (+12%–18%) to future therapy options compared with subtype B. Topologies of subtype mutation networks were mostly similar.Conclusions. We find clear differences in DRM outcomes following first-line failure, suggesting subtype-specific ecological or biological factors that determine DRM patterns.

Antiretroviral resistance, genotypic characterization and origin of Human Immunodeficiency Virus among the infected wives of Intravenous drug users in Manipur

“…Although Manipur has been being one of the hard hit epicenters of the HIV/AIDS epidemic in India since the first detection of HIV-1 in the year 1990, study on drug resistance profile among the HIV infected wives of IDUs of Manipur is limited. Many of HIV/AIDS patients may have been treated inappropriately due to lack of sequence interpretations of newly mutated virus which enhance the viral activity even in presence of antiviral drugs 12 . The surveillance of transmitted and acquired drug resistant strains of HIV-1 is one of the priorities for HIV/AIDS prevention and control.…”

Divergent HIV-1 strains (CRF92_C2U and CRF93_cpx) co-circulating in the Democratic Republic of the Congo: Phylogenetic insights on the early evolutionary history of subtype C

“…Several studies suggest the preferential selection of certain drug resistance mutations in subtype C ( Loemba et al 2002 ; Brenner et al 2003 , 2006 ; Skhosana et al 2015 ; Huang et al 2016 ) when compared to subtype B, which is the most prevalent genetic form in high-income countries. However, subtype C accounts for approximately 50 per cent of current HIV infections.…”

Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study

“…There are few studies comparing HIVDR profiles between subtypes in diverse, wellcharacterized cohorts. One such instance is Huang et al's analysis of a multi-cohort, multi-subtype dataset 21 , building upon earlier work by Kantor et al 22 . The latter study found little difference in resistance mutation positions between non-B and subtype B viruses.…”